Lippuner, Kurt; Buchard, P A; De Geyter, C; Imthurn, B; Lamy, O; Litschgi, M; Luzuy, F; Schiessl, K; Stute, P; Birkhäuser, M (2012). Recommendations for raloxifene use in daily clinical practice in the Swiss setting. European spine journal, 21(12), pp. 2407-17. Berlin: Springer-Verlag 10.1007/s00586-012-2404-y
|
Text
586_2012_Article_2404.pdf - Published Version Available under License Publisher holds Copyright. Download (285kB) | Preview |
Raloxifene is the first selective estrogen receptor modulator that has been approved for the treatment and prevention of osteoporosis in postmenopausal women in Europe and in the US. Although raloxifene reduces the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer, it is approved in that indication in the US but not in the EU. The aim was to characterize the clinical profiles of postmenopausal women expected to benefit most from therapy with raloxifene based on published scientific evidence to date.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Orthopaedic, Plastic and Hand Surgery (DOPH) > Clinic of Osteoporosis 04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology |
UniBE Contributor: |
Lippuner, Kurt, Stute, Petra, Birkhäuser, Martin |
ISSN: |
0940-6719 |
Publisher: |
Springer-Verlag |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:24 |
Last Modified: |
05 Dec 2022 14:07 |
Publisher DOI: |
10.1007/s00586-012-2404-y |
PubMed ID: |
22739699 |
Web of Science ID: |
000311780000001 |
BORIS DOI: |
10.7892/boris.8673 |
URI: |
https://boris.unibe.ch/id/eprint/8673 (FactScience: 214285) |
Actions (login required)
 |
Edit item |